Silexion Therapeutics Corp
SLXNW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0002022416
No open-market purchases or sales by Silexion Therapeutics Corp insiders were filed in the last 90 days; 19 institutions reported holding it in 13F filings for Q2 2026, worth $70.3K in total; no superinvestor holds it.
Other share classesSLXN
Q4 2024 vs. Q3 2024
How the institutions holding Silexion Therapeutics Corp changed between Q3 2024 and Q4 2024.
All holders in Q4 2024All holders in Q3 2024
| Measure | Q3 2024 | Q4 2024 | Change |
|---|---|---|---|
| Holders | 32 | 26 | −6 |
| Shares | 2.75M | 2.63M | −116.2K (−4.2%) |
| Value | $106.1K | $91.7K | −$14.4K (−13.6%) |
New holders (1)
Institutions that held Silexion Therapeutics Corp at the end of Q4 2024 but not at the end of Q3 2024.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| GTS Securities LLC | 23,498 | $799 | 0.00% |
Sold out (7)
Institutions that held Silexion Therapeutics Corp at the end of Q3 2024 and filed for Q4 2024 without it.
| Institution | Shares, Q3 2024 | Value, Q3 2024 |
|---|---|---|
| Highbridge Capital Management LLC | – | $3.50K |
| Gabelli & Co Investment Advisers, Inc. | 38,150 | $1.21K |
| Susquehanna International Group, LLP | 34,577 | $1.10K |
| Gabelli Funds LLC | 30,496 | $967 |
| Walleye Capital LLC | 21,000 | $666 |
| Blue Owl Capital Holdings LP | 12,500 | $396 |
| CNH Partners LLC | 12,313 | $390 |